Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.

E, Araki; S, Yamashita; H, Arai; K, Yokote; J, Satoh; T, Inoguchi; J, Nakamura; H, Maegawa; N, Yoshioka; Y, Tanizawa; H, Watada; H, Suganami; S, Ishibashi

doi:10.2337/dc17-1589

Public

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.

Shared by NobleBlocks on Jan 3, 2018 • 12:00 AM UTC

Authors:

Araki E

Yamashita S

Arai H

Abstract

<h4>Objective</h4>Type 2 diabetes is frequently complicated with atherogenic dyslipidemia. This study aimed to evaluate the efficacy and safety of pemafibrate (K-877) in patients with type 2 diabetes comorbid with hypertriglyceridemia.<h4>Research design and methods</h4>Patients were randomly assign...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!